Capastat Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Mechanism of Action
Capastat Indications
Indications
Capastat Dosage and Administration
Adult
Children
Capastat Contraindications
Not Applicable
Capastat Boxed Warnings
Boxed Warning
May be associated with worse clinical outcomes (eg, decreased effectiveness, increased mortality) compared with other parenteral therapy for pulmonary MDR-TB. Use with extreme caution in patients with renal insufficiency or preexisting auditory impairment.
Capastat Warnings/Precautions
Warnings/Precautions
See Boxed warning. Should reserve for those with resistance to injectable aminoglycosides and limited treatment options. Renal or auditory impairment. Risk for additional cranial nerve VIII impairment or renal injury. Assess audiometric measurements and vestibular function prior to initiation and at regular intervals during therapy. Monitor renal function at baseline and weekly during therapy; reduce dose or discontinue if BUN>30mg/dL or if renal function decreases. Monitor hepatic function and serum potassium, magnesium, and calcium levels. Elderly. Pregnancy: may be teratogenic. Nursing mothers.
Capastat Pharmacokinetics
Elimination
Capastat Interactions
Interactions
Concomitant streptomycin, other parenteral antituberculars: not recommended. Increased toxicity with other neuro/ototoxic drugs (eg, aminoglycosides); use cautiously.
Capastat Adverse Reactions
Adverse Reactions
Capastat Clinical Trials
See Literature
Capastat Note
Not Applicable
Capastat Patient Counseling
See Literature